Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

A New Germline Mutation In Kit Associated With Diffuse Cutaneous Mastocytosis In A Chinese Family

Diffuse Cutaneous Mastocytosis: a Case Report and Mutation Analysis of the KIT Gene

Amyloidosis Cutis Dyschromica Cases Caused by GPNMB Mutations with Different Inheritance Patterns.

Prevalence and impact of the KIT M541L variant in patients with mastocytosis

A Novel Splicing Mutation of Kit Results in Piebaldism and Auburn Hair Color in A Chinese Family

[Identification of novel KIT gene mutations in two Chinese families with piebaldism].

Multiple Lentigines and Cutaneous Hyperpigmentation Caused by a KIT Mutation

Identification of a Novel Mutation in the KITLG Gene in a Chinese Family with Familial Progressive Hyper- and Hypopigmentation

Familial Gastrointestinal Stromal Tumors with KIT Germline Mutation in a Chinese Family: A Case Report.

A Novel Mutation of the KIT Gene in a Chinese Family with Piebaldism

Next-Generation Sequencing Detection and Characterization of A Heterozygous Novel Splice Junction Mutation in the 2b Domain of Krt1 in A Family with Diffuse Palmoplantar Keratoderma

Case Report: A Missense Mutation in Dyskeratosis Congenita 1 Leads to a Benign Form of Dyskeratosis Congenita Syndrome With the Mucocutaneous Triad

Cutaneous Hyperpigmentation and Familial Gastrointestinal Stromal Tumor Associated With Germline KIT Mutation Treated With Imatinib: A Chinese Case Report

Ovarian germ cell tumor/mastocytosis with KIT mutation: A unique clinicopathological entity

Identification Of A Novel Mutation And A De Novo Mutation In Dkc1 In Two Chinese Pedigrees With Dyskeratosis Congenita

The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Identification of Novel KMT2D Mutations in Two Chinese Children with Kabuki Syndrome: a Case Report and Systematic Literature Review

Novel pathogenic variants in KIT gene in three Chinese piebaldism patients

Data from Large-Scale Analysis of <i>KIT</i> Aberrations in Chinese Patients with Melanoma

Cutaneous Hyperpigmentation and Familial Gastrointestinal Stromal Tumor Associated with Germline KIT Mutation Treated with Imatinib

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.